Meningococcal Disease: Recommended vaccinations
Back to search
Export to spreadsheet
  General recommendation
  Recommendation for specific groups only
  Catch-up (e.g. if previous doses missed)
 		 Vaccination not funded by the National Health system
 		 Mandatory vaccination
WeeksMonthsYears
62345611121314152101112131415161718192429≥ 30
Austria
MenB1
MenB1
MCV4/MenB
MCV4
Belgium
MCV4
MCV4
Bulgaria
Croatia
Cyprus
MCV4
MPSV42
Czechia
MenB3
MenB3
MCV4/MenB3
MCV4/MenB3
Denmark
Estonia
Finland
MCV44
MCV4/MenB5
MCV4/MenB6
MenB7
MCV48
France
MenB9
MenB
MCV410
MCV4/MenB
MCV411
MCV4/MenB
Germany
MenB
MenB
MenB - MenC12
MenC
Greece
MCV4/MenB
MenC
MenC
MCV4
MCV4
MCV4/MenB
Hungary
MenC
MenC
MenC13
Iceland
MCV4
Ireland
MenB
MenB
MenC
MenB
MenC14
MCV4
Italy
MenB15
MenB15
MCV4
MenB15
MenB15
MCV416
Latvia
Liechtenstein
MCV417
MCV418
Lithuania
MenB
MenB
MenB19
Luxembourg
MenB
MenB
MenB
MCV4
MCV4
Malta
MenB
MCV4
MenB
MenB
MCV4
MCV4
Netherlands
MCV420
MCV420
Norway
Poland
MenC
MenC
Portugal
MenB
MenB
MenB - MenC
Romania
Slovakia
MenB
MenB
MCV4/MenB
MCV4/MenB21
Slovenia
Spain
MenB22
MenB - MenC22
MenB - MenC22
MCV423
MCV424
Sweden

Footnotes:

  1. Please refer to official recommendations for timing and number of doses required according to age. For infants, 3 doses from 3 months of age with at least one month interval - Booster between 13-15 months.
  2. vaccines only given on specific indications
  3. MenB vaccination for small infants is covered by health insurance if the schedule is started before the age of 1 year and vaccination for adolescents if vaccination is started at the age interval from 14 to 16 years. MCV4 vaccination for toodlers is covered by health insurance if is administered at the age interval from 12 to 23 months and vaccination for adolescents if vaccination is started at the age interval from 14 to 16 years. Vaccination with MenB and MCV4 vaccines is covered by health insurance for persons of all ages with immune disorders. More details of the recommendation is available at: https://szu.cz/wp-content/uploads/2024/01/2024-Recommendation-for-vaccination-against-IMD.pdf
  4. MCV4: The vaccination series includes a total of two doses, with the second doses been administered at least two months after the first dose. In addition, one booster dose will be given at twelve months of age, no earlier than two months after the second dose of Nimenrix. Nimenrix is administered to children aged six weeks to under two years, while Menveo is recommended for individuals aged two years and older. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, please refer to the official information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote
  5. MCV4: The vaccination series includes a total of two doses, with the second doses been administered at least two months after the first dose. In addition, one booster dose will be given at twelve months of age, no earlier than two months after the second dose of Nimenrix. Nimenrix is administered to children aged six weeks to under two years, while Menveo is recommended for individuals aged two years and older. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, please refer to the official information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote MenB: Bexsero vaccine is administered to infants aged 2 to 5 months as a series of three doses, spaced at least one month apart. A booster dose is then recommended at 12 to 15 months of age, provided that at least six months have passed since the last dose. The number of doses and administration schedule vary depending on the recipient's age. For detailed guidance, please refer to the official information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-b-rokote
  6. Booster doses are administered only under specific circumstances, based on the age at which previous doses were received. Additional information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote AND https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-b-rokote
  7. Booster doses are administered only under specific circumstances, based on the age at which previous doses were received. Additional information available at: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote AND https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-b-rokote
  8. A MCV4 dose is administered to military conscripts upon commencement of their service (compulsory for men and voluntary for women). While the majority begin service between the ages of 19 and 20, the official age range for enlistment spans from 18 to 29 years.
  9. Vaccination introduced in 2022. Mandatory since January 2025.
  10. Introduced in January 2025 in replacement of monovalent MenC
  11. More information available at: https://www.service-public.fr/particuliers/actualites/A16520
  12. Introduction of MenB vaccine in January 2025
  13. Since January 1st, 2017, the meningococcal C vaccine is offered to all children aged under 2 years with 100% reimbursement on a voluntary-based approach.
  14. Hib/MenC combined vaccine
  15. Please refer to local recommendations for age of administration. MenB should not to be co-administered with other vaccinations.
  16. Meningococcal ACWY, one dose for adolescents age 12-18
  17. Not part of the routine vaccination programme but can be offered by health professionals. Catch-up possible until 5 years of age.
  18. Not part of the routine vaccination programme but can be offered by health professionals. Catch-up possible until 20 years of age.
  19. Can be administered concomitantly with MMR
  20. More information available at https://rijksvaccinatieprogramma.nl/vaccinaties/menacwy
  21. One dose of each vaccine if given between 14 and 15 years
  22. Additional information available at https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/comoTrabajamos/enf-meningococica.htm
  23. One dose at 12 years to individuals who have not received any doses of MCV4 since 10 years of age. Additional information available at https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/comoTrabajamos/enf-meningococica.htm
  24. The catch-up vaccination programme for individuals aged 13 to 18 years will be introduced gradually (more information available at: https://www.sanidad.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/adolescentes-meningo/home.htm